Simulations Plus (NASDAQ:SLP – Get Free Report) is anticipated to announce its Q4 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $17.44 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.
Simulations Plus Stock Performance
NASDAQ SLP opened at $18.50 on Tuesday. Simulations Plus has a one year low of $11.09 and a one year high of $21.01. The stock has a 50-day moving average of $18.44 and a 200 day moving average of $16.37. The company has a market capitalization of $374.16 million, a price-to-earnings ratio of 46.25 and a beta of 1.31.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Simulations Plus in a report on Tuesday, October 6th. BTIG Research reissued a “neutral” rating on shares of Simulations Plus in a report on Wednesday, October 7th. Seven investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Simulations Plus has an average rating of “Reduce” and an average price target of $17.25.
Read Our Latest Research Report on Simulations Plus
About Simulations Plus
Simulations Plus, Inc develops software and provides consulting services for pharmaceutical research and development. Its technology helps scientists model how drugs are absorbed, distributed, metabolized and excreted in the body, supporting decisions throughout the drug-development process.
The company’s product portfolio includes GastroPlus, a physiologically based pharmacokinetic modeling platform; ADMET Predictor, which supports the prediction of drug absorption, distribution, metabolism, excretion and toxicity properties; and DILIsym, a platform designed to evaluate the risk of drug-induced liver injury.
See Also
- Five stocks we like better than Simulations Plus
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
